Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2011-1-4
pubmed:abstractText
Dimethyloxalylglycine (DMOG) is an inhibitor of prolyl-4-hydroxylase domain (PHD) enzymes that regulate the stability of hypoxia-inducible factor (HIF). We investigated the effect of DMOG on the outcome after permanent and transient middle cerebral artery occlusion (p/tMCAO) in the rat. Before and after pMCAO, rats were treated with 40 mg/kg, 200 mg/kg DMOG, or vehicle, and with 40 mg/kg or vehicle after tMCAO. Serial magnetic resonance imaging (MRI) was performed to assess infarct evolution and regional cerebral blood flow (rCBF). Both doses significantly reduced infarct volumes, but only 40 mg/kg improved the behavior after 24 hours of pMCAO. Animals receiving 40 mg/kg were more likely to maintain rCBF values above 30% from the contralateral hemisphere within 24 hours of pMCAO. DMOG after tMCAO significantly reduced the infarct volumes and improved behavior at 24 hours and 8 days and also improved the rCBF after 24 hours. A consistent and significant upregulation of both mRNA and protein levels of vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS) was associated with the observed neuroprotection, although this was not consistently related to HIF-1? levels at 24 hours and 8 days. Thus, DMOG afforded neuroprotection both at 24 hours after pMCAO and at 24 hours and 8 days after tMCAO. This effect was associated with an increase of VEGF and eNOS and was mediated by improved rCBF after DMOG treatment.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1559-7016
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
31
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
132-43
pubmed:dateRevised
2011-4-8
pubmed:meshHeading
pubmed-meshheading:20407463-Amino Acids, Dicarboxylic, pubmed-meshheading:20407463-Animals, pubmed-meshheading:20407463-Behavior, Animal, pubmed-meshheading:20407463-Blood Gas Analysis, pubmed-meshheading:20407463-Blotting, Western, pubmed-meshheading:20407463-Brain Chemistry, pubmed-meshheading:20407463-Brain Ischemia, pubmed-meshheading:20407463-Chronic Disease, pubmed-meshheading:20407463-Gene Expression, pubmed-meshheading:20407463-Hypoxia-Inducible Factor 1, alpha Subunit, pubmed-meshheading:20407463-Infarction, Middle Cerebral Artery, pubmed-meshheading:20407463-Ischemic Attack, Transient, pubmed-meshheading:20407463-Magnetic Resonance Imaging, pubmed-meshheading:20407463-Male, pubmed-meshheading:20407463-Neuroprotective Agents, pubmed-meshheading:20407463-Nitric Oxide Synthase Type III, pubmed-meshheading:20407463-RNA, pubmed-meshheading:20407463-Rats, pubmed-meshheading:20407463-Rats, Wistar, pubmed-meshheading:20407463-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:20407463-Vascular Endothelial Growth Factor A
pubmed:year
2011
pubmed:articleTitle
Neuroprotection by dimethyloxalylglycine following permanent and transient focal cerebral ischemia in rats.
pubmed:affiliation
Nuffield Department of Clinical Medicine, Acute Stroke Programme, University of Oxford, Oxford, UK. simon.nagel@med.uni-heidelberg.de
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't